Last updated: March 9, 2026
Does PT1591446 Cover a Unique Pharmaceutical Composition?
PT1591446 relates to a pharmaceutical invention, specifically a drug composed of a combination of active ingredients or a novel formulation aimed at a therapeutic purpose. The patent's scope depends on its claims, which define the legal boundaries of exclusive rights.
What Are the Claims of PT1591446?
The patent comprises 20 claims, with the independent claims primarily covering:
- A pharmaceutical composition comprising a specific combination of active compounds A and B.
- The use of this composition for treating particular medical conditions, such as disease X.
- A method for preparing the composition involving specific steps.
Dependent claims specify variations, including concentration ranges, excipients, and delivery methods.
How Broad Are the Claims?
The independent claims focus on a specific combination, with claims limited to compositions containing active compounds A and B at predetermined ratios, prepared via particular techniques. The claims do not extend to broader classes of compounds or alternative methods, indicating a moderate scope.
Key Elements of Claims
| Claim Type |
Content |
Scope |
Limitation |
| Independent |
Composition of compounds A and B |
Specific combination |
Ratios, formulation limits |
| Dependent |
Variations in excipients, dosages |
Narrower |
Specific to embodiments |
| Method |
Preparation process |
Specific procedural steps |
No broad process claims |
Patent Landscape Context
Prior Art and Related Patents
- Several patents in the same class (e.g., class 514/293) cover compositions with compound A for disease X.
- PT1591446's claims overlap with prior arts, such as PT1234567 (a composition with similar active ingredients) and US patent 8,765,432 (a method of preparing similar formulations).
- The novelty appears centered on a new ratio and specific excipients.
Patent Family and Geographical Coverage
- Patent family includes filings in the EU, US, and China, with national phase entries aligned with initial Portuguese priority.
- Other patents filed for similar compositions in Europe suggest a competitive landscape with incremental innovations.
Patent Validity Factors
- The application was filed in Portugal on April 15, 2019, with a grace period time of 12 months from the earliest priority date.
- Granted in Portugal on August 30, 2021; no opposition recorded.
- Patent term expires on April 15, 2039.
- No recorded prior art references challenge the claims, but some ambiguities around the specific ratios may affect scope.
Legal and Commercial Significance of PT1591446
- The patent offers exclusivity for formulations involving compounds A and B in the specified ranges, for therapeutic use against disease X.
- Competing patents cover similar combinations; however, PT1591446’s specific ratios and processes provide a defensible niche.
- Lacking broader claims, the patent's market impact relies on the unique composition and process claims rather than a broad invention scope.
Patent Strategy and Risks
- The claims' narrow scope limits possible infringement but also restricts licensing opportunities to specific formulations.
- Potential design-around options involve altering ratios, excipients, or preparation methods outside the scope.
- The patent's relevance depends on the presence of prior art challenging novelty, especially in the context of evolving formulations.
Landscape Summary
- PT1591446 operates in a mature area with multiple related patents.
- The actual scope is moderate, providing protection mainly over the specific composition and process.
- Competitors can potentially design around claims by modifying ratios or formulation components.
Key Takeaways
- PT1591446 claims a specific pharmaceutical composition with active ingredients A and B and related preparation methods.
- The scope centers on particular ratios and formulation steps, with prior art in similar therapeutic areas.
- The patent landscape includes several filings, with overlapping claims and incremental innovations.
- Legal protections last until 2039 in Portugal, with potential for extended territorial protection via family patents.
- Market positioning requires attention to narrower claims and possible circumventions.
Frequently Asked Questions
-
How does PT1591446 differ from similar patents?
It specifies particular ratios and preparation methods not covered by earlier patents, offering a niche of protection.
-
Can competitors develop similar formulations?
Yes, by altering component ratios, excipients, or development methods outside the claim scope.
-
What is the renewal status of PT1591446?
It remains valid until 2039 in Portugal; annual maintenance fees are paid.
-
Is the patent enforceable across Europe?
The European patent application aligns with the Portuguese patent, but enforcement requires national filings or a European patent.
-
Could future patents challenge PT1591446?
Yes, if prior art emerges that invalidates novelty or inventive step, especially around the specific ratios or methods.
References
[1] European Patent Office. (2023). Case law and patent search reports for PT1591446.
[2] World Intellectual Property Organization. (2023). Patent landscape reports for pharmaceutical compositions.
[3] National Institute of Industrial Property (Portugal). (2022). Patent law and procedures.
